Find
7119
related chemicals for you
CAS:63-42-3
Molecular Formula:C12H22O11
Lactobiose; D-Lactose; Lactose,Anhydrous; D-Lactose Anhydrous; Anhydrous Lactose; Screening Lactose; Crushing Lactose
Brief Introduction
This product is a nutritional sweetener, which is widely used in making baby food, candy, margarine, culture medium, color layer absorbent and shaping medicine.
CAS:638-07-3
Molecular Formula:C6H9ClO3
4-Chloro Ethyl Acetoacetate; Ethyl (Chloroacetyl)Acetate; Ethyl G-Chloroacetoacetate; Ethyl 4-Chloroacetoa; 4-Chloro-Acetoacetic acid Ethyl Ester; 4-Chloro-3-oxo-Butanoic acid Ethyl Ester; Ethyl 4-Chloro-3-Oxobutanoate; Ethyl 4-Chloro Aceto Acetate
Brief Introduction
It is used as the intermediate of medicine and pesticide. It is an intermediate of pharmaceutical synthesis and the intermediate of oxiracetam and L-carnitine. Amlodipine besylate for synthesis
CAS:641571-10-0
Molecular Formula:C28H22F3N7O
Tasigna; Nilotinib (Amn-107); Its Intermediates; Nilotinib For Research; Nilotinib(Amn 107); Nilotinib,Amn107,Tasigna; Amn 107; Nilotinib D6
Brief Introduction
Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
CAS:644-36-0
Molecular Formula:C9H10O2
O-Tolylacetic Acid; O-Methylphenylacetic Acid; 2-Methylphenyl Acetic Acid; 2-Tolylacetic Acid; O-Tolyacetic Acid; 2-Methylbenzeneacetic Acid
Brief Introduction
This product is mainly used as an intermediate in organic synthesis.
CAS:656247-18-6
Molecular Formula:C33H39N5O7S
3-Z-[1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Methyl-Amino)-Anilino)-1-Phenyl-Methylene]-6-Methoxycarbonyl-2-Indolinone Monoethanesulphonate; Ethanesulfonic Acid - Methyl (3Z)-3-{[(4-{Methyl[(4-Methyl-1-Pipe Razinyl)Acetyl]Amino}Phenyl)Amino](Phenyl)Methylene}-2-Oxo-6-Indo Linecarboxylate (1:1); Methyl (3Z)-3-[({4-[N-Methyl-2-(4-Methylpiperazin-1-Yl)Acetamido]Phenyl}Amino)(Phenyl)Methylidene]-2-Oxo-2,3-Dihydro-1H-Indole-6-Carboxylate Ethanesulfonate Salt; 3-Z-[1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Methyl-Amino)-Anilino)-1-Phenyl-Methylene]-6-Methoxycarbonyl-2-Indolinone Monoethanesulfonate Salt; (3S,5S)-3,5-Bis[[(1,1-Dimethylethyl)Dimethylsilyl]Oxy]-1-Hydroxy-Cyclohexanecarboxylic Acid Methyl Ester
Brief Introduction
Nitanib ethylsulfonate is a small molecule inhibitor of multi receptor tyrosine kinase and non receptor tyrosine kinase. In 2014, it was approved by FDA for the first time, and was developed and sold by bringer Ingelheim company for the first time. It has been approved by the US Food and Drug Administration (FDA), the European Drug Administration (EMA) and the agency for drugs and medical devices (PMDA) for the treatment of idiopathic pulmonary fibrosis, and by EMA for non-small cell lung cancer.
Inquiry ( 
10
 
/ 10
 )
Clear All
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >